Guidelines

South African Dyslipidaemia Guideline Consensus Statement

E.Q. Klug, F.J. Raal, A.D. Marais, M-R. Taskinen, A.J. Dalby, C. Schamroth, N. Rapeport, D. Jankelow, D.J. Blom, R. Catsicas, D.A. Webb
South African Family Practice | Vol 57, No 2 : March/April| a4261 | DOI: https://doi.org/10.4102/safp.v57i2.4261 | ©
Submitted: 21 April 2015 | Published: 13 March 2015

About the author(s)

E.Q. Klug,, South Africa
F.J. Raal,, South Africa
A.D. Marais,, South Africa
M-R. Taskinen,, Finland
A.J. Dalby,, South Africa
C. Schamroth,, South Africa
N. Rapeport,, South Africa
D. Jankelow,, South Africa
D.J. Blom,, South Africa
R. Catsicas,, South Africa
D.A. Webb,, South Africa

Full Text:

PDF (110KB)

Abstract

The European Society of Cardiology together with the European Atherosclerosis Society published updated dyslipidaemia guidelines in 2011. SA Heart and the Lipid and Atherosclerosis Society of Southern Africa officially adopt these guidelines. This statement adapts aspects of the guidelines to the South African situation. Using the updated Framingham risk charts, interventional strategies are based according to the cardiovascular risk score and low-density lipoprotein cholesterol (LDL-C) levels. The Framingham risk score refers to the 10-year risk of any cardiovascular event, and includes four categories of risk. Treatment targets are those of the European guidelines. The LDL-C goal is 1.8 mmol/l for the very high-risk group (>30%), 2.5 mmol/l for the high-risk group (15 - 30%), and 3 mmol/l for those below 15% risk. Intensive management of dyslipidaemia in South Africa will significantly reduce the cardiovascular disease health burden.

Keywords

South African Dyslipidaemia Guideline

Metrics

Total abstract views: 1349
Total article views: 1007


Crossref Citations

No related citations found.